Peptide bioregulator
Cartalax
Cartalax is the app's name for the tripeptide Ala-Glu-Asp (AED), which nine papers test in cell cultures and rats; no result in people was identified.
Cartalax after one dose: 50% at ~0.5 h, 25% at 1 h, 12.5% at 1.5 h.
Drawn from the half-life in the app's model, ~0.5 h. The model's figures
- Compound
- Cartalax
- Symbol
- CTX
- Family
- Healing peptides
- Parts
- 13
- References
- 11
- Checked
- Last reviewed . Sources are listed below.
Overview
Cartalax is the app's name for the tripeptide Ala-Glu-Asp (AED).1 Two of the papers call the same peptide T-31, and name the kidney polypeptide complex and a second short peptide, T-35 (EDL), beside it.2,3 The app's notes place it in the Khavinson short-peptide "bioregulator" tradition, the same lineage as Epithalon, Vilon, Pinealon and Thymalin, and say it is not the tetrapeptide Cortagen (Ala-Glu-Asp-Pro). The app grades the evidence for Cartalax as limited.
The name Cartalax does not appear in any of the nine records read; a search of PubMed for it returned six records, and the nine below are the ones that test Ala-Glu-Asp. Eight of the nine list Khavinson as an author and the ninth comes from the St. Petersburg Institute of Bioregulation and Gerontology.2,4,5,6,7,1,8,9,3 Several of the nine include authors at other institutions, in Moscow, Italy and Ukraine.1,8,5 Five of the nine report experiments in kidney cells, kidney tissue or kidney function in rats, and the others use skin fibroblasts or stem cells.4,2,3,5,6,7,9,1,8
The app's notes say Cartalax is marketed for cartilage and connective tissue. None of the nine papers reports an experiment on cartilage or chondrocytes.8 One of them, the 2019 stem-cell paper, lists for AED in a table of the peptides' biological activity "Normalization of cartilaginous tissue functions, for example, in human with osteoartrosis", while its own experiments were in periodontal ligament stem cells.8
How it works
Sources in this part
The only mechanism offered in the nine records is cellular, and it comes from cell culture and computer models, not from measurements in people. Khavinson and colleagues, Advances in Gerontology, 2014, write that "models of interaction of peptides with various sites of DNA were constructed" for AED and EDL.4 They report that both peptides "form most energetically favorable complexes with d(ATATATATAT)2 sequences in minor groove of DNA" and conclude that the interaction with DNA "is the cause of gene expression, encoded marker of ageing in renal cells".4 Ashapkin and colleagues, Molecular Biology Reports, 2020, studied expression of the IGF1, FOXO1, TERT, TNKS2 and NFκB genes in human embryo bone marrow mesenchymal stem cells after AED, KED or KE.1 They report IGF1 expression "being enhanced by 3.5-5.6 fold upon the addition of the peptides", and that "AED, KED, and KE stimulated expression of the NFκB gene in both models".1 In the same record the FOXO1 effects are attributed to KED (inhibition by 1.6-2.3 fold) and KE (an increase of about two-fold in the "stationary" model only), and the TNKS2 effect to KED; the record names no FOXO1 or TNKS2 effect for AED.1 Fridman and colleagues, Bulletin of Experimental Biology and Medicine, 2020, report that AED "activates the synthesis of sirtuin-1, sirtuin-6, and collagen I in human skin fibroblasts during their replicative aging".9 All of these are findings in cultured cells; none is a finding in a living animal or a person.1,9
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~0.5 h
- Bioavailability
- 90%
- Typical dose
- 1–10 mg/day
- Route
- SubQ
- Time to peak
- ~0.5 h
Sources in this part
The table sets the app's figures beside what the nine papers report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~0.5 h (30 minutes) | None of the nine papers reports a half-life |
| Bioavailability (SubQ) | 90% | None of the nine papers reports a bioavailability |
| Time to peak | ~0.5 h | None of the nine papers reports a time to peak |
The app's notes say that no published pharmacokinetic data exists in any species and that its values follow the short-peptide class pattern rather than a measurement of this compound. A search of PubMed, ClinicalTrials.gov and DailyMed identified no label, regulator document or registry entry that gives a half-life for Ala-Glu-Asp. The app's figures therefore have no figure from a source beside them, and nothing in the papers read contradicts them. A 2026 review of epitalon, the four-amino-acid peptide Ala-Glu-Asp-Gly, notes that "Human pharmacokinetics, dose-ranging studies, and dedicated prospective safety trials also remain unavailable"; the sentence is about epitalon, not about AED.10
Human studies
No controlled trial or other study in people was identified in PubMed, ClinicalTrials.gov or DailyMed under the names Cartalax, Ala-Glu-Asp or AED. The table lists the nine laboratory papers that test AED, with the material studied in the People column.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Khavinson and colleagues, Advances in Gerontology 20144 | Cell culture and DNA-interaction models; funding not stated in the record | None; ageing renal cell culture, young and aged cells | AED and EDL; concentration and length not given in the record | AED and EDL increased cell proliferation, lowered p16, p21 and p53 expression and raised SIRT-6 expression |
| Khavinson and colleagues, Bulletin of Experimental Biology and Medicine 20142 | Cell culture; markers Ki-67, p53, MMP-14 and IL-8; funding not stated in the record | None; primary kidney cell cultures during aging | Calf-kidney polypeptide complex, T-31 (AED), T-35 (EDL); concentration and length not given | The complex and T-31 activated cell renewal processes; MMP-14 is named as the target of T-35 |
| Chalisova and colleagues, Bulletin of Experimental Biology and Medicine 20153 | Organotypic tissue culture (ex vivo); funding not stated in the record | None; kidney explants from young and old rats | Calf-kidney complex, T-31 (AED), T-35 (EDL); concentration and length not given | T-31 and T-35 stimulated proliferation and reduced apoptosis, but to a lesser degree than the complex |
| Zamorskii and colleagues, Advances in Gerontology 20185 | Rat experiment; group sizes not given in the record | None; old rats | Kidney complex, AED, EDL, AEDG; dose, route and length not given | AED with the complex and EDL increased diuresis by 1.2 to 1.4 times and with the complex reduced urine protein by 1.5 to 2.8 times |
| Zamorskii and colleagues, Bulletin of Experimental Biology and Medicine 20156 | Rat experiment; group sizes not given in the record | None; rats with cisplatin-induced acute renal failure | Kidney complex, AED, EDL, AEDG; dose, route and length not given | AED decreased protein excretion and urinary electrolyte concentration; normalised diuresis and filtration rate are reported for the complex, EDL and AEDG |
| Lin'kova and colleagues, Bulletin of Experimental Biology and Medicine 20167 | Cell culture, confocal microscopy; funding not stated in the record | None; skin fibroblasts aging in culture | KE, KED, AED, AEDG; concentration and length not given | All four peptides inhibited MMP-9 synthesis and enhanced Ki-67 and CD98hc; AED and AEDG suppressed caspase-dependent apoptosis |
| Caputi and colleagues, International Journal of Immunopathology and Pharmacology 20198 | Cell culture; no funding and no conflicts declared | None; human periodontal ligament stem cells | AEDG, KE, AED, KED and a mixture, 0.01 µg/mL, medium replaced every 3 days; 10 days of induction | In basal cultures AEDG, KE, AED, KED and the mixture all increased GAP43 over control; in differentiated cells GAP43 and Nestin rose most with the mixture and KED, and the record does not name AED alone for the differentiated-cell increases |
| Ashapkin and colleagues, Molecular Biology Reports 20201 | Cell culture, two ageing models ("passages" and "stationary"); funding not stated in the record | None; human embryo bone marrow mesenchymal stem cells | AED, KED, KE at nanomolar concentrations; length not given | IGF1 expression enhanced 3.5-5.6 fold with the peptides; AED, KED and KE stimulated NFκB expression |
| Fridman and colleagues, Bulletin of Experimental Biology and Medicine 20209 | Cell culture, immunocytochemistry and confocal microscopy; funding not stated in the record | None; human skin fibroblasts in replicative aging | KE and AED; concentration and length not given | AED activated sirtuin-1, sirtuin-6 and collagen I synthesis; KE reduced IL-1, NF-κB and TGF-β |
Deeper analysis: kidney cell and tissue cultures
The three culture papers were published in 2014 and 2015 from the St. Petersburg group, and all three test AED beside a second short peptide, EDL.4,2,3 Khavinson and colleagues, Advances in Gerontology, 2014, grew ageing renal cells and report that AED and EDL "increase cell proliferation, decreasing expression of marker of aging p16, p21, p53 and increasing expression of SIRT-6 in young and aged renal cell culture".4 The record adds that "The reduction of SIRT-6 synthesis in cell is one of the causes of cell senescence".4 Khavinson and colleagues, Bulletin of Experimental Biology and Medicine, 2014, measured Ki-67 and p53 as renewal markers, MMP-14 as a marker of extracellular matrix remodelling and IL-8 as a marker of immune response in primary kidney cell cultures.2 Their conclusion is that "The complex of renal polypeptides and T-31 peptide activate cell renewal processes during aging of the renal epithelium, while gelatinase MMP-14 is the target of T-35 peptide", so the MMP-14 finding is about EDL and not about AED.2 Chalisova and colleagues, Bulletin of Experimental Biology and Medicine, 2015, used organotypic kidney tissue cultures from young and old rats, and report that the complex "enhances expression of proliferation marker Ki-67 and reduces expression of proapoptotic peptide p53".3 For AED (T-31) and EDL (T-35) the same record says they "also stimulate proliferation and reduce apoptosis of the kidney cells, but to a lesser degree than the polypeptide complex".3 The authors state that the results "provide the basis for further investigation of the polypeptide complex as a preparation for the therapy of kidney diseases", which names the complex and not AED.3 The PubMed records for the three papers give no concentrations, culture lengths, numbers of cultures, funding statements or limitations, so those cannot be reported here.
Deeper analysis: kidney function in rats
Zamorskii and colleagues reported two rat experiments on kidney function, one in old rats in Advances in Gerontology in 2018 and one in rats with cisplatin-induced acute renal failure in Bulletin of Experimental Biology and Medicine in 2015.5,6 The first author is at the Bukovinian State Medical University in Ukraine, and the co-authors Linkova, Nichik and Khavinson are listed at the Saint-Petersburg Institute of Bioregulation and Gerontology.5 In the 2018 experiment, the record reports that "Administration of PKC, peptides AED and EDL increased diuresis by 1,2-1,4 times" and that "PKC and peptide AED reduced urine protein level and protein excretion by 1,5-2,8 times".5 It also reports that "Peptides AED and EDL increased sodium excretion by 1,3 and 1,6 times, respectively", and that PKC, AED and EDL increased distal sodium transport by 1.2 to 1.3 times.5 A different result is given for AEDG, the four-amino-acid peptide: "Renal effects of peptide AEDG resulted in a reduction of glomerular filtration rate by 21%".5 The record gives no group sizes, doses, route or duration, and states no limitations or funding. On safety, the record states that "In kidney tissue a stimulation of the antioxidant enzymes activity on the background of inhibition of the peroxidation processes intensity was observed, which in complex with morphological data evidences the absence of nephrotoxic effects"; the sentence does not say which of the kidney complex, AED, EDL or AEDG it covers, and the record gives no group sizes, doses or duration.5 The authors conclude that "PKC, peptides AED, EDL and AEDG may be considered as nephroprotective agents in kidney aging", a conclusion drawn from rat data.5 In the 2015 cisplatin experiment, the record says "AED peptide decreased protein excretion and electrolyte concentration in the urine".6 The normalisation of diuresis, urinary creatinine, glomerular filtration rate and sodium resorption is attributed to "Polypeptide complex from the kidney and peptides EDL and AEDG", and AED is not in that list.6 The record says "EDL peptide produced was potent nephroprotective effect", again a statement about EDL and not about AED.6 The 2015 record also gives no group sizes, doses, funding or limitations.
Deeper analysis: skin fibroblast cultures
Lin'kova and colleagues, Bulletin of Experimental Biology and Medicine, 2016, tested KE, KED, AED and AEDG in skin fibroblasts aging in culture by immunofluorescent confocal microscopy.7 They report that "All studied peptides inhibited MMP-9 synthesis" and enhanced Ki-67 and CD98hc expression, and that "Peptides AED and AEDG suppressed caspase-dependent apoptosis that increases during aging of cell cultures".7 The caspase result is stated for AED and AEDG and not for KE or KED.7 Fridman and colleagues, Bulletin of Experimental Biology and Medicine, 2020, compared KE and AED in human skin fibroblasts during replicative aging, and write that AED "activates the synthesis of sirtuin-1, sirtuin-6, and collagen I", which they say "attests to its geroprotective effect".9 In the same record the anti-inflammatory result, lower IL-1, NF-κB and TGF-β synthesis, is reported for KE and not for AED.9 Neither record gives concentrations, culture lengths, funding or limitations.
Deeper analysis: stem cell cultures
Caputi and colleagues, International Journal of Immunopathology and Pharmacology, 2019, is the only one of the nine read in full text; it was written by a group at the University of Chieti-Pescara in Italy with Khavinson and colleagues from St. Petersburg.8 The study used human periodontal ligament stem cells, grown with or without AEDG, KE, AED, KED and a mixture of all four, each "diluted in phosphate-buffered saline (PBS) at a concentration of 0.01 µg/mL" and replaced every 3 days.8 Proliferation was measured by an MTT assay, and the paper reports that "peptides did not induce an inhibition on cell proliferation", with the combination showing "a positive action on the proliferation rate starting at 1 week of culture".8 In basal cultures, "the peptides AEDG, KE, AED, and KED and their mixture increased the synthesis of the GAP43 protein in hPDLSCs cultures compared to the control cells".8 In differentiated cells the larger effects were with the mixture and KED, and the paper's summary says GAP43 rose "with a compound of all studied peptides and with KED alone".8 The authors conclude that "short peptides could be employed as a supplementary substance in culture medium to enhance neurogenic differentiation capacity in vitro for future regenerative cell therapy".8 The paper has no section naming limitations; its footnotes state "The author(s) received no financial support for the research, authorship, and/or publication of this article" and "declared no potential conflicts of interest".8 Ashapkin and colleagues, Molecular Biology Reports, 2020, authored by Moscow State University and St. Petersburg groups, add that "the peptides studied at nanomolar concentrations modulate the expression of some genes known to be involved in cell aging".1 That PubMed record gives no funding statement or limitations.
Doses reported in studies and on labels
No label for Ala-Glu-Asp was identified in DailyMed, and no dose in people appears in any of the nine papers.
| Source | Material studied | Concentration or dose reported |
|---|---|---|
| Caputi and colleagues 20198 | Human periodontal ligament stem cells | 0.01 µg/mL of each peptide in phosphate-buffered saline, added to the medium and replaced every 3 days; 10 days of induction |
| Ashapkin and colleagues 20201 | Human embryo bone marrow mesenchymal stem cells | "nanomolar concentrations" |
| The other seven papers4,2,3,5,6,7,9 | Renal cells, kidney explants, rats and skin fibroblasts | No concentration or dose in the PubMed record |
| The app's typical dose | Not a study or label figure | 1–10 mg/day, SubQ, with no figure from a study or label beside it |
Side effects reported
Sources in this part
No adverse-event or safety report in people was identified for Ala-Glu-Asp. A 2018 old-rat kidney paper states that "In kidney tissue a stimulation of the antioxidant enzymes activity on the background of inhibition of the peroxidation processes intensity was observed, which in complex with morphological data evidences the absence of nephrotoxic effects"; the sentence does not say which of the kidney complex, AED, EDL or AEDG it covers.5 The same paper reports a 21% reduction in glomerular filtration rate with AEDG, a different peptide.5 In stem-cell culture, the 2019 paper states that the peptides "do not negatively influence the proliferation rate".8 These are findings in rats and cultured cells and are not safety data for people.
Bloodwork and markers
Sources in this part
The app lists hs-CRP, creatinine and eGFR as markers. None of the nine records mentions C-reactive protein or eGFR, and none measures any marker in a person. In rats, the cisplatin experiment measured urinary creatinine, urinary creatinine excretion and glomerular filtration rate, and attributes their normalisation to the kidney complex, EDL and AEDG.6 The 2018 old-rat paper measured glomerular filtration rate as well, with the 21% reduction attributed to AEDG.5 The app's reason for listing creatinine and eGFR is not stated in the records; the repeated organ signal in the papers is kidney.
Regulatory and anti-doping status
Sources in this part
The World Anti-Doping Agency's 2026 Prohibited List text does not name Cartalax or Ala-Glu-Asp.11 Its S0 class, "NON-APPROVED SUBSTANCES", covers any pharmacological substance not addressed elsewhere in the list "with no current approval by any governmental regulatory health" authority for human therapeutic use.11 Whether that class applies to AED is not stated in the list, and the list's own S0 examples name other compounds.11 No DailyMed label for Ala-Glu-Asp was identified, and no ClinicalTrials.gov study of it was identified. No European or Australian regulator document for it was searched, so nothing is stated about those regulators.
What is not known
- No study in people was identified, so the effect of AED on any outcome in a person, and any adverse event in people, is not described by the sources read.
- No half-life, bioavailability or time to peak is reported in the nine papers, and the app's figures follow a class pattern, not a measurement of AED.4
- None of the nine papers reports a cartilage or chondrocyte experiment, although the app's notes describe the compound as marketed for cartilage and connective tissue.8
- Eight of the nine are in the Khavinson group's network, and none is described in the records as an independent replication.2
- Several kidney results are for the kidney complex, EDL or AEDG and not for AED; in the cisplatin paper AED is named only for decreased protein excretion and urinary electrolyte concentration.6
- A 2026 review of epitalon states that "no adequately powered randomized trial has demonstrated clinical efficacy for aging, longevity, sleep disorders, musculoskeletal disease, pain, or another regenerative indication"; that statement is about epitalon, a related peptide, and not about AED.10
Frequently asked questions
What is Cartalax?
What is the half-life of Cartalax?
The app lists a half-life of about 0.5 hours (30 minutes), and none of the nine papers reports a half-life. The app's notes say the value follows the short-peptide class pattern rather than a measurement of this compound.
Has Cartalax been studied in people?
Has Cartalax been tested in cartilage?
What have the studies on Cartalax reported?
Is Cartalax banned by WADA?
The 2026 WADA Prohibited List text does not name Cartalax or Ala-Glu-Asp.11 Its S0 class covers substances with no current approval by any governmental regulatory health authority for human therapeutic use, and the list does not say whether AED falls in it.11 The list states that a substance meeting the S0 description is "prohibited at all times".11
Is Cartalax the same as Epitalon?
Is Cartalax the same as Cortagen?
No: the app's notes say Cortagen is the tetrapeptide Ala-Glu-Asp-Pro, whereas Cartalax is the tripeptide Ala-Glu-Asp.
What is the bioavailability of Cartalax?
The app lists a bioavailability of 90%, and none of the nine papers reports a bioavailability.
Are side effects of Cartalax reported?
No adverse-event report in people was identified. A 2018 old-rat kidney paper reports "the absence of nephrotoxic effects" in kidney tissue, without saying in the sentence which of the kidney complex, AED, EDL or AEDG it covers.5
Guides, tools and comparisons
References
- Ashapkin V, et al. Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Mol Biol Rep 2020. PMID 32399807
- Khavinson VKh, et al. Peptides regulate expression of signaling molecules in kidney cell cultures during in vitro aging. Bull Exp Biol Med 2014. PMID 24958378
- Chalisova NI, et al. Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals. Bull Exp Biol Med 2015. PMID 26033601
- Khavinson VKh, et al. [Tripeptides slow down aging process in renal cell culture]. Adv Gerontol 2014. PMID 25946838
- Zamorskii II, et al. [The influence of peptides on the morphofunctional state of old rats kidneys.] Adv Gerontol 2018. PMID 30607912
- Zamorskii II, et al. Peptides Restore Functional State of the Kidneys During Cisplatin-Induced Acute Renal Failure. Bull Exp Biol Med 2015. PMID 26515176
- Lin'kova NS, et al. Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro. Bull Exp Biol Med 2016. PMID 27259496
- Caputi S, et al. Effect of short peptides on neuronal differentiation of stem cells. Int J Immunopathol Pharmacol 2019. PMID 30791821
- Fridman NV, et al. Comparison of the Effects of KE and AED Peptides on Functional Activity of Human Skin Fibroblasts during Their Replicative Aging. Bull Exp Biol Med 2020. PMID 33231794
- Jain A, et al. Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence. Int J Mol Sci 2026. PMC13664938
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list